ArticleScientific reports2017
Circulating microRNA-214 and -126 as potential biomarkers for canine neoplastic disease.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 56 citations in OpenAlex.
- Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease.Molecular oncology · 2026Article
- The role of epigenetic alterations in canine mammary cancer.The Journal of reproduction and development · 2026Review
- MicroRNA differential expression analysis in canine visceral hemangiosarcoma formalin-fixed, paraffin-embedded tissues.Frontiers in veterinary science · 2026Article
- Exploring the role of miR-126 in diabetes and its complications: a comprehensive review.Diabetology & metabolic syndrome · 2025Review
- MicroRNAs in serum and tissue can differentiate splenic hemangiosarcoma from other splenic masses in dogs.Veterinary pathology · 2025Article
- Chemical Sensors and Biosensors for Point-of-Care Testing of Pets: Opportunities for Individualized Diagnostics of Companion Animals.ACS sensors · 2025Review
- Stability of microRNAs in Canine Serum-A Prerequisite for Use as Biomarkers in Tumour Diagnostics.Veterinary sciences · 2025Article
- Low-Invasive Biomarkers of Canine Mammary Tumours.Veterinary medicine and science · 2025Review
- DR-70 (fibrinogen-fibrin degradation products) as a prognostic biomarker in dogs with neoplasms.The veterinary quarterly · 2024Article
- Exploring the role of microRNAs as diagnostic and prognostic biomarkers in canine mammary tumors.GeroScience · 2024Review
- Exploring the contrasts: in-depth analysis of human and canine mammary tumors - discoveries at the frontier.Medicine and pharmacy reports · 2024Review
- Canine Mammary Tumors: Classification, Biomarkers, Traditional and Personalized Therapies.International journal of molecular sciences · 2024Review
- Epigenetic regulation in muscle-invasive urothelial carcinoma of the bladder in the dog, a translational model of human cancer.Veterinary oncology (London, England) · 2024Article
- MicroRNAs and angiosarcoma: are there promising reports?Frontiers in oncology · 2024Review
- Melanoma of the dog and cat: consensus and guidelines.Frontiers in veterinary science · 2024Review
- Article
- Review
- miRNA Profiles of Canine Intestinal Carcinomas, Lymphomas and Enteritis Analysed by Digital Droplet PCR from FFPE Material.Veterinary sciences · 2023Article
- A review on microRNA detection and expression studies in dogs.Frontiers in veterinary science · 2023Review
- Blood biomarkers for canine cancer, from human to veterinary oncology.Veterinary and comparative oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating microRNAs in the blood may provide diagnostic and prognostic information about canine neoplastic diseases, and their profiles may be conserved between human and canine species. We performed RT-qPCR to obtain the profiles of circulating plasma microRNA-214 and -126 in total 181 cases of canine neoplastic diseases and healthy controls. MicroRNA-214 levels were high in 2 epithelial tumours (thyroid and mammary carcinomas) and 4 non-epithelial tumours (osteosarcoma, histiocytic sarcoma, chondrosarcoma, and hemangiosarcoma). In contrast, microRNA-126 levels were high in 6 epithelial tumours (mammary, hepatocellular, squamous cell, thyroid, transitional cell carcinomas, and adenocarcinoma) and 4 non-epithelial tumours (osteosarcoma, mast cell tumour, melanoma, and hemangiosarcoma). The diagnostic potential of microRNA-214 was relatively high in sarcomas, whereas that of microR-126 was high in most types of the tumours. MicroRNA-214 and -126 were prognostic predictors in 2 groups (adenocarcinoma and non-epithelial tumours except for osteosarcoma) and 3 groups (epithelial tumours, adenocarcinoma, and melanoma), respectively. Additionally, the microRNA levels did not show a strong correlation with the other clinical parameters. In conclusion, circulating microRNA-214 and -126 have the potential to be diagnostic and prognostic biomarkers for canine neoplastic diseases. Furthermore, their profiles may be key references as well for exploring novel biomarkers for human cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.